Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000077.xml
Semin Thromb Hemost 2000; 26(5): 513-520
DOI: 10.1055/s-2000-13207
DOI: 10.1055/s-2000-13207
Lipoproteins and the Endothelium: Insights from Clinical Research
Klaus A. Dugi1 , Daniel J. Rader2- 1Department of Internal Medicine I, Endocrinology and Metabolism, Heidelberg University, Heidelberg, Germany
- 2University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
Further Information
Publication History
Publication Date:
31 December 2000 (online)
ABSTRACT
Elevated plasma levels of atherogenic lipoproteins such as low-density lipoprotein (LDL) and remnant lipoproteins and low levels of HDL cholesterol constitute major risk factors for the development of atherothrombotic disease. In addition to their role in the initiation and propagation of atherosclerosis, hyperlipidemia also causes endothelial dysfunction. In addition, hyperlipidemia has an influence on thrombosis by modulating levels of prothrombotic and fibrinolytic factors, thus promoting the final step in the atherosclerotic process, vascular occlusion. In the last 5 years, randomized, prospective, placebo-controlled studies aimed at reducing plasma levels of atherogenic lipoproteins have demonstrated a significant effect on cardiovascular morbidity and all-cause mortality in both primary and secondary prevention. Although the mechanisms underlying the clinical benefit of lipid-lowering therapy remain uncertain, the lowering of lipids has been associated with improved endothelial function and a less thrombotic state, two factors that could play a role in the benefit of lipid lowering. This review focuses on recent clinical research related to the impact of lipoproteins and lipid-lowering therapy on endothelial function and plasma levels of prothrombotic and fibrinolytic factors.
KEYWORD
Atherothrombotic disease - endothelial dysfunction - hyperlipidemia - statins - treatment
REFERENCES
- 1 Stamler J, Wentworth D, Neaton J D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded?. <~>Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA . 1986; 256 2823-2828
- 2 Genest J J, McNamara J R, Salem D N, Schaefer E J. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol . 1991; 67 1185-1189
- 3 Gordon T, Castelli W P, Hjortland M C, Kannel W B, Dawber T R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med . 1977; 62 707-714
- 4 Miller G J, Miller N E. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet . 1975; 1 16-19
- 5 Krauss R M, Lindgren F T, Williams P T. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet . 1987; 2 62-66
- 6 Phillips N R, Waters D, Havel R J. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation . 1993; 88 2762-2770
- 7 Kugiyama K, Doi H, Takazoe K. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Improvement of endothelial vasomotor dysfunction by treatment with alpha-tocopherol in patients with high remnant lipoproteins levels. J Am Coll Cardiol . 1999; 33 1512-1518
- 8 Miller N E, Hammett F, Saltissi S. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br Med J (Clin Res Ed) . 1981; 282 1741-1744
- 9 Ballantyne F C, Clark R S, Simpson H S, Ballantyne D. High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects. Metabolism . 1982; 31 433-437
- 10 Puchois P, Kandoussi A, Fievet P. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis . 1987; 68 35-40
- 11 Lamarche B, Tchernof A, Moorjani S. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation . 1997; 95 69-75
- 12 Stampfer M J, Krauss R M, Ma J. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA . 1996; 276 882-888
- 13 Gardner C D, Fortmann S P, Krauss R M. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA . 1996; 276 875-881
- 14 Quyyumi A A. Endothelial function in health and disease: New insights into the genesis of cardiovascular disease. Am J Med . 1998; 105 32S-39S
- 15 Vogel R A. Coronary risk factors, endothelial function, and atherosclerosis: A review. Clin Cardiol . 1997; 20 426-432
- 16 Playford D A, Watts G F. Special article: Non-invasive measurement of endothelial function. Clin Exp Pharmacol Physiol . 1998; 25 640-643
- 17 Pitkanen O P, Raitakari O T, Niinikoski H. Coronary flow reserve is impaired in young men with familial hypercholesterolemia. J Am Coll Cardiol . 1996; 28 1705-1711
- 18 Yokoyama I, Murakami T, Ohtake T. Reduced coronary flow reserve in familial hypercholesterolemia. J Nucl Med . 1996; 37 1937-1942
- 19 Drexler H, Zeiher A M, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by l-arginine. Lancet . 1991; 338 1546-1550
- 20 Chowienczyk P J, Watts G F, Cockcroft J R, Ritter J M. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet . 1992; 340 1430-1432
- 21 Zeiher A M, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest . 1993; 92 652-662
- 22 Seiler C, Hess O M, Buechi M, Suter T M, Krayenbuehl H P. Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries. Circulation . 1993; 88 2139-2148
- 23 Yokoyama I, Ohtake T, Momomura S. Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. Circulation . 1996; 94 3232-3238
- 24 Yokoyama I, Ohtake T, Momomura S. Impaired myocardial vasodilation during hyperemic stress with dipyridamole in hypertriglyceridemia. J Am Coll Cardiol . 1998; 31 1568-1574
- 25 Yokoyama I, Ohtake T, Momomura S. Altered myocardial vasodilatation in patients with hypertriglyceridemia in anatomically normal coronary arteries. Arterioscler Thromb Vasc Biol . 1998; 18 294-299
- 26 Doi H, Kugiyama K, Ohgushi M. Remnants of chylomicron and very low density lipoprotein impair endothelium-dependent vasorelaxation. Atherosclerosis . 1998; 137 341-349
- 27 Kugiyama K, Doi H, Motoyama T. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation . 1998; 97 2519-2526
- 28 Chowienczyk P J, Watts G F, Wierzbicki A S. Preserved endothelial function in patients with severe hypertriglyceridemia and low functional lipoprotein lipase activity. J Am Coll Cardiol . 1997; 29 964-968
- 29 Vogel R A, Corretti M C, Plotnick G D. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol . 1997; 79 350-354
- 30 Hackman A, Abe Y, Insull Jr W. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation . 1996; 93 1334-1338
- 31 Toikka J O, Ahotupa M, Viikari J S. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis . 1999; 147 133-138
- 32 Zeiher A M, Schachlinger V, Hohnloser S H, Saurbier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation . 1994; 89 2525-2532
- 33 Simpson H C, Mann J I, Meade T W. Hypertriglyceridaemia and hypercoagulability. Lancet . 1983; 1 786-790
- 34 Silveira A, Karpe F, Blombãck M. Activation of coagulation factor VII during alimentary lipemia. Arterioscler Thromb . 1994; 14 60-69
- 35 Woodward M, Lowe G D, Rumley A. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol . 1997; 97 785-797
- 36 Hamsten A, de Faire U, Walldius G. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet . 1987; 2 3-9
- 37 Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med . 1985; 313 1557-1563
- 38 Sandset P M, Lund H, Norseth J, Abildgaard U, Ose L. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb . 1991; 11 138-145
- 39 Hansen J B, Huseby N E, Sandset P M. Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb . 1994; 14 223-229
- 40 Zitoun D, Bara L, Basdevant A, Samama M M. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias. Arterioscler Thromb Vasc Biol . 1996; 16 77-81
- 41 Carvalho A C, Colman R W, Lees R S. Platelet function in hyperlipoproteinemia. N Engl J Med . 1974; 290 434-438
- 42 Aoki I, Aoki N, Kawano K. Platelet-dependent thrombin generation in patients with hyperlipidemia. J Am Coll Cardiol . 1997; 30 91-96
- 43 Brunzell J D. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis af Inherited Disease New York: McGraw-Hill, 1995: 1913-1932
- 44 Benlian P, De Gennes L J, Foubert L. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene [published erratum appears in N Engl J Med 1997;336:451]. N Engl J Med . 1996; 19 335:848-854
- 45 The Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: Lancet . 1994; 19 344:1383-1389
- 46 Sacks F M, Pfeffer M A, Moye L A. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med . 1996; 335 1001-1009
- 47 The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med . 1998; 339 1349-1357
- 48 Shepherd J, Cobbe S M, Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med . 1995; 333(20) 1301-1307
- 49 Downs J R, Clearfield M, Weis S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA . 1998; 279 1615-1622
- 50 LaRosa J C, He J, Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA . 1999; 282 2340-2346
- 51 Rubins H B, Robins S J, Collins D. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med . 1999; 341 410-418
- 52 Harrison D G, Armstrong M L, Freiman P C, Heistad D D. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest . 1987; 80 1808-1811
- 53 Leung W H, Lau C P, Wong C K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet . 1993; 341 1496-1500
- 54 Seiler C, Suter T M, Hess O M. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J Am Coll Cardiol . 1995; 26 1615-1622
- 55 Egashira K, Hirooka Y, Kai H. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation . 1994; 89 2519-2524
- 56 Treasure C B, Klein J L, Weintraub W S. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med . 1995; 332 481-487
- 57 Anderson T J, Meredith I T, Yeung A C. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med . 1995; 332 488-493
- 58 Stroes E S, Koomans H A, de Bruin W T, Rabelink T J. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet . 1995; 19 346:467-471
- 59 Vogel R A, Corretti M C, Plotnick G D. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol . 1996; 77 37-40
- 60 van Boven J A, Jukema J W, Zwinderman A H. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. Circulation . 1996; 94 1503-1505
- 61 Andrews T C, Raby K, Barry J. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation . 1997; 95 324-328
- 62 Baller D, Notohamiprodjo G, Gleichmann U. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation . 1999; 99 2871-2875
- 63 Huggins G S, Pasternak R C, Alpert N M, Fischman A J, Gewirtz H. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation . 1998; 98 1291-1296
- 64 Pitt B, Waters D, Brown W V. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med . 1999; 341 70-76
- 65 Gould K L, Martucci J P, Goldberg D I. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation . 1994; 89 1530-1538
- 66 O'Driscoll G, Green D, Taylor R R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation . 1997; 95 1126-1131
- 67 Tamai O, Matsuoka H, Itabe H. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation . 1997; 95 76-82
- 68 Dupuis J, Tardif J C, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation . 1999; 99 3227-3233
- 69 Clarkson P, Adams M R, Powe A J. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest . 1996; 97 1989-1994
- 70 Creager M A, Gallagher S J, Girerd X J. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest . 1992; 90 1248-1253
- 71 John S, Schlaich M, Langenfeld M. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: A randomized, placebo-controlled, double-blind study. Circulation . 1998; 98 211-216
- 72 Laufs U, La F, Plutzky J, Liao J K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation . 1998; 97 1129-1135
- 73 Branchi A, Rovellini A, Sommariva D, Gugliandolo A G, Fasoli A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost . 1993; 70 241-243
- 74 Marais A D, Firth J C, Bateman M E. Atorvastatin: An effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol . 1997; 17 1527-1531
- 75 Davidson M, McKenney J, Stein E. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol . 1997; 79 1475-1481
- 76 Wierzbicki A S, Lumb P J, Semra Y K, Crook M A. Effect of atorvastatin on plasma fibrinogen [letter]. Lancet . 1998; 351 569-570
- 77 Rosenson R S, Tangney C C. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA . 1998; 279 1643-1650
- 78 Lacoste L, Lam J Y, Hung J. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation . 1995; 92 3172-3177
